Daniel Grosu

Dr. Daniel Grosu serves as Senior Vice President and Chief Medical Officer at Sequenom. Dr. Grosu serves as Senior Vice President and Chief Medical Officer. Prior to joining Sequenom, Dr. Grosu served as Illumina's first Chief Medical Officer and subsequently as the Vice President of Clinical Development and Medical Affairs. He established the Clinical Development and Medical Affairs functions at Illumina, and led the team that performed the clinical studies supporting the FDA clearance and CE marking of the MiSeqDx NGS platform. Prior to Illumina, Dr. Grosu held positions of increasing responsibility in the medical diagnostics space at Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Ortho Clinical Diagnostics (a Johnson & Johnson company at the time). Dr. Grosu holds an MD (with Distinction in Research) from Saint Louis University School of Medicine and an MBA from the University of Oxford.